Epinephrine itself costs about $1 to manufacture. A vial of the drug in ampule form runs roughly $1.17, and the spring-loaded autoinjector device that delivers it costs only a few dollars to produce. Yet a two-pack of EpiPens sells for $350 to $700 at U.S. pharmacies. The gap between production cost and shelf price comes down to a combination of patent strategies, limited competition, and a drug pricing system that rewards middlemen.
The Drug Is Cheap, the Device Is Not
Epinephrine is a hormone your body produces naturally. It’s been used in medicine for over a century, and the compound itself is long off patent. There’s no secret formula driving up the price. The expense is almost entirely tied to the delivery device: the auto-injector mechanism with its spring, needle, and safety features. Even that device costs only a few dollars to manufacture, not accounting for licensing royalties. So the price tag on an EpiPen has very little to do with what’s physically inside the box.
Patent Strategies That Block Competition
One of the biggest reasons prices stay high is a tactic sometimes called “evergreening.” Manufacturers make incremental modifications to the delivery device, things like new locking assemblies to hold the needle cover in different positions, and patent each tweak. These successive patents extend the period of market exclusivity well beyond what the original design would have allowed. It’s not the drug being protected; it’s the specific way the device clicks, locks, and fires. Each new patent makes it harder for competitors to design a functionally similar product without infringing.
This creates a kind of legal moat around the product. A generic competitor can’t simply copy the epinephrine (which is trivial) and pair it with any injector. They need to engineer around every active patent on the device, get FDA approval for their specific design, and then manufacture it at scale. That process takes years and hundreds of millions of dollars, which deters all but the largest generic manufacturers from trying.
Generic Competition Has Been Slow to Arrive
When the FDA approved Teva’s generic EpiPen, it was hailed as a breakthrough that would bring prices down. It didn’t work out that way. Within months of approval, Teva’s launch stalled due to supply problems. At one point, Teva’s generic held just 3% of the market by prescription volume, down from 7% a month earlier. Mylan (now Viatris), which makes the branded EpiPen, held roughly 64% of the market with its branded and authorized generic versions combined, in what was a $750 million per year U.S. market.
The authorized generic from Viatris and a generic version from Amneal Pharmaceuticals have helped bring cash prices down somewhat, but the market remains concentrated. When only a handful of companies sell a product that millions of people need to carry at all times (and replace yearly as it expires), there’s little pressure to compete aggressively on price.
How Middlemen Push Prices Higher
The U.S. drug pricing system includes pharmacy benefit managers, or PBMs, who negotiate rebates from manufacturers on behalf of insurers. In theory, rebates should lower what patients pay. In practice, they often do the opposite. Research from USC Schaeffer found that every $1 increase in rebates paid by a manufacturer is associated with a $1.17 increase in that drug’s list price. Manufacturers raise the sticker price to fund the rebates, and patients who are uninsured or stuck with high deductibles end up paying based on that inflated list price.
This dynamic creates a perverse incentive. PBMs tend to favor drugs offering higher rebates on their formularies, even when a competing drug has a lower actual cost. Manufacturers respond by setting higher list prices so they can offer bigger rebates, which keeps their product on insurance formularies. The result is a pricing spiral where the list price climbs but much of the money flows to intermediaries rather than back to patients. When Mylan reported that it took home about $274 from a $600 two-pack, the rest was absorbed by this chain of distributors, wholesalers, and PBMs.
The Same Product Costs Far Less Abroad
In the United Kingdom, a comparable pair of epinephrine auto-injectors costs the National Health Service about $69. The same product that runs $600 or more in the U.S. costs less than its leather carrying case in Britain. The difference comes down to how prices are set. The UK government negotiates directly with pharmaceutical companies to cap costs, while the U.S. system relies on private negotiations between manufacturers and PBMs, with no ceiling on what can be charged. Countries with centralized price negotiation consistently pay a fraction of what American patients pay for the same medications.
Newer Options and What They Cost
A needle-free nasal spray called neffy, made by ARS Pharmaceuticals, recently entered the market as the first non-injection alternative. Its retail price ranges from $199 at some pharmacies for a two-pack to over $700 at list price before insurance. Commercial insurance plans have generally started covering it, though most require prior authorization. The manufacturer offers a copay card that can reduce out-of-pocket costs to $25 for commercially insured patients, but that discount doesn’t apply to Medicare or Medicaid. So far, 19 major insurers including UnitedHealthcare, Cigna, and Tricare cover the nasal spray, though uptake among government-insured patients remains much lower.
For the traditional injectors, manufacturer assistance programs exist but come with limitations. Viatris offers a patient assistance program that may provide EpiPens for free to people with demonstrated financial need, and Kaléo (which makes AUVI-Q) has a similar program for uninsured patients facing financial hardship. Manufacturer coupons can save up to $300 per EpiPen two-pack, but eligibility often depends on your insurance status, and these programs require applying, waiting, and sometimes having your doctor submit paperwork.
Why It Stays This Way
Epinephrine pricing persists because of a combination of factors that reinforce each other. Patents on the device limit who can compete. The small number of competitors that do exist face manufacturing and supply chain hurdles. The rebate system rewards high list prices. And patients with severe allergies have no real choice about whether to buy the product. When demand is inelastic, meaning people will pay whatever is charged because the alternative is risking death from anaphylaxis, there’s little market force pushing prices down. The drug itself has always been cheap. Everything around it is where the cost lives.